| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Shiono, T Kobayashi, R Takahashi, G Sun, M Abe, D Zhang, L Wang, X Piao, Y Takagi, R Mineki, H Taka, N Tada, S Sonobe, S Momose, M Ueda, O Hin. The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition. Oncogene. vol 27. issue 52. 2008-11-18. PMID:18695678. |
tuberin, a tumor-suppressor protein produced by the tuberous sclerosis gene tsc2, downregulates the rheb-mtor-s6k pathway (mtor axis). |
2008-11-18 |
2023-08-12 |
human |
| M Shiono, T Kobayashi, R Takahashi, G Sun, M Abe, D Zhang, L Wang, X Piao, Y Takagi, R Mineki, H Taka, N Tada, S Sonobe, S Momose, M Ueda, O Hin. The G1556S-type tuberin variant suppresses tumor formation in tuberous sclerosis 2 mutant (Eker) rats despite its deficiency in mTOR inhibition. Oncogene. vol 27. issue 52. 2008-11-18. PMID:18695678. |
comparison of the effects of human tuberin mutations, such as g1556s, suggests that pathways other than the mtor axis might also be involved in the pathogenesis of tuberous sclerosis. |
2008-11-18 |
2023-08-12 |
human |
| Agus Suryawan, Asumthia S Jeyapalan, Renan A Orellana, Fiona A Wilson, Hanh V Nguyen, Teresa A Davi. Leucine stimulates protein synthesis in skeletal muscle of neonatal pigs by enhancing mTORC1 activation. American journal of physiology. Endocrinology and metabolism. vol 295. issue 4. 2008-11-17. PMID:18682538. |
neither leucine nor rapamycin affected the phosphorylation of amp-activated protein kinase (ampk), pkb, or tuberous sclerosis complex (tsc)2, signaling components that reside upstream of mtor. |
2008-11-17 |
2023-08-12 |
Not clear |
| G F L Hofbauer, A Marcollo-Pini, A Corsenca, A D Kistler, L E French, R P Wüthrich, A L Serr. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. The British journal of dermatology. vol 159. issue 2. 2008-11-12. PMID:18547304. |
the mtor inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. |
2008-11-12 |
2023-08-12 |
Not clear |
| Margit Rosner, Markus Hengstschläge. Cytoplasmic and nuclear distribution of the protein complexes mTORC1 and mTORC2: rapamycin triggers dephosphorylation and delocalization of the mTORC2 components rictor and sin1. Human molecular genetics. vol 17. issue 19. 2008-11-07. PMID:18614546. |
the distinct cytoplasmic and nuclear upstream and downstream effectors of mtor are involved in many cancers and human genetic diseases, such as tuberous sclerosis, peutz-jeghers syndrome, von hippel-lindau disease, neurofibromatosis type 1, polycystic kidney disease, alzheimer's disease, cardiac hypertrophy, obesity and diabetes. |
2008-11-07 |
2023-08-12 |
human |
| Margit Rosner, Michaela Hanneder, Nicol Siegel, Alessandro Valli, Christiane Fuchs, Markus Hengstschläge. The mTOR pathway and its role in human genetic diseases. Mutation research. vol 659. issue 3. 2008-10-14. PMID:18598780. |
mutations in the mtor pathway component genes tsc1, tsc2, lkb1, pten, vhl, nf1 and pkd1 trigger the development of the syndromes tuberous sclerosis, peutz-jeghers syndrome, cowden syndrome, bannayan-riley-ruvalcaba syndrome, lhermitte-duclos disease, proteus syndrome, von hippel-lindau disease, neurofibromatosis type 1, and polycystic kidney disease, respectively. |
2008-10-14 |
2023-08-12 |
human |
| Chong Chen, Yu Liu, Runhua Liu, Tsuneo Ikenoue, Kun-Liang Guan, Yang Liu, Pan Zhen. TSC-mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species. The Journal of experimental medicine. vol 205. issue 10. 2008-10-14. PMID:18809716. |
the tuberous sclerosis complex (tsc)-mammalian target of rapamycin (mtor) pathway is a key regulator of cellular metabolism. |
2008-10-14 |
2023-08-12 |
Not clear |
| Carolyn L Buller, Robert D Loberg, Ming-Hui Fan, Qihong Zhu, James L Park, Eileen Vesely, Ken Inoki, Kun-Liang Guan, Frank C Brosiu. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. American journal of physiology. Cell physiology. vol 295. issue 3. 2008-10-09. PMID:18650261. |
since gsk-3 can inhibit mammalian target of rapamycin (mtor) signaling via phosphorylation of the tuberous sclerosis complex subunit 2 (tsc2) tumor suppressor, we investigated whether chronic gsk-3 effects on glucose uptake and glut1 expression depended on tsc2 phosphorylation and tsc inhibition of mtor. |
2008-10-09 |
2023-08-12 |
Not clear |
| Sangyeul Han, Rochelle M Witt, Túlio M Santos, Carolyn Polizzano, Bernardo L Sabatini, Vijaya Rames. Pam (Protein associated with Myc) functions as an E3 ubiquitin ligase and regulates TSC/mTOR signaling. Cellular signalling. vol 20. issue 6. 2008-09-29. PMID:18308511. |
the tumor suppressor tuberin, encoded by the tuberous sclerosis complex (tsc) gene tsc2, negatively regulates the mammalian target of rapamycin (mtor) pathway, which plays a key role in the control of cell growth and proliferation. |
2008-09-29 |
2023-08-12 |
rat |
| Karen H Lu, Weiguo Wu, Bhuvanesh Dave, Brian M Slomovitz, Thomas W Burke, Mark F Munsell, Russell R Broaddus, Cheryl Lyn Walke. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. vol 14. issue 9. 2008-09-18. PMID:18451215. |
although tuberous sclerosis complex 2 (tsc2) is the "gatekeeper" for mtor activation, little is known about defects in the tsc2 tumor suppressor or signaling pathways that regulate tsc2, such as lkb1/amp-activated protein kinase, in the development of endometrial carcinoma. |
2008-09-18 |
2023-08-12 |
Not clear |
| Dan Ehninger, Sangyeul Han, Carrie Shilyansky, Yu Zhou, Weidong Li, David J Kwiatkowski, Vijaya Ramesh, Alcino J Silv. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nature medicine. vol 14. issue 8. 2008-08-21. PMID:18568033. |
notably, we show that a brief treatment with the mtor inhibitor rapamycin in adult mice rescues not only the synaptic plasticity, but also the behavioral deficits in this animal model of tuberous sclerosis. |
2008-08-21 |
2023-08-12 |
mouse |
| Dan Ehninger, Sangyeul Han, Carrie Shilyansky, Yu Zhou, Weidong Li, David J Kwiatkowski, Vijaya Ramesh, Alcino J Silv. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nature medicine. vol 14. issue 8. 2008-08-21. PMID:18568033. |
the results presented here reveal a biological basis for some of the cognitive deficits associated with tuberous sclerosis, and they show that treatment with mtor antagonists ameliorates cognitive dysfunction in a mouse model of this disorder. |
2008-08-21 |
2023-08-12 |
mouse |
| Han C Dan, Albert S Baldwi. Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. Journal of immunology (Baltimore, Md. : 1950). vol 180. issue 11. 2008-07-18. PMID:18490760. |
mtor is negatively controlled by the tuberous sclerosis complex 1/2 (tsc1/2), and activation of akt induces phosphorylation of tsc2, which blocks the repressive tsc1/2 activity. |
2008-07-18 |
2023-08-12 |
Not clear |
| Y Sun, Y Fang, M-S Yoon, C Zhang, M Roccio, F J Zwartkruis, M Armstrong, H A Brown, J Che. Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proceedings of the National Academy of Sciences of the United States of America. vol 105. issue 24. 2008-07-18. PMID:18550814. |
the tuberous sclerosis complex 1 and 2 (tsc1/2) proteins and their target, the small gtpase rheb, constitute a key regulatory pathway upstream of mtor. |
2008-07-18 |
2023-08-12 |
Not clear |
| X Yang, C Yang, A Farberman, T C Rideout, C F M de Lange, J France, M Z Fa. The mammalian target of rapamycin-signaling pathway in regulating metabolism and growth. Journal of animal science. vol 86. issue 14 Suppl. 2008-07-01. PMID:17998426. |
upstream elements of the mtor-signaling pathway include ras-homolog enriched in brain, and tuberous sclerosis complex 1 and 2, with tuberous sclerosis complex 2 as the linker between phosphatidylinositol 3-kinase/protein kinase b or ras-raf-mitogen-activated protein kinase-extracellular signal-regulated protein kinase pathways and the mtor pathway. |
2008-07-01 |
2023-08-12 |
Not clear |
| Lynsey Meikle, Kristen Pollizzi, Anna Egnor, Ioannis Kramvis, Heidi Lane, Mustafa Sahin, David J Kwiatkowsk. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 28. issue 21. 2008-06-26. PMID:18495876. |
response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mtor) inhibitors: effects on mtorc1 and akt signaling lead to improved survival and function. |
2008-06-26 |
2023-08-12 |
mouse |
| Yutaka Shigeyama, Toshiyuki Kobayashi, Yoshiaki Kido, Naoko Hashimoto, Shun-Ichiro Asahara, Tomokazu Matsuda, Akihiko Takeda, Tae Inoue, Yuki Shibutani, Maki Koyanagi, Tohru Uchida, Maki Inoue, Okio Hino, Masato Kasuga, Tetsuo Nod. Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice. Molecular and cellular biology. vol 28. issue 9. 2008-06-19. PMID:18316403. |
given the role of tuberous sclerosis complex 2 (tsc2) as an upstream molecule of mtor (mammalian target of rapamycin), we examined the effect of tsc2 deficiency on beta-cell function. |
2008-06-19 |
2023-08-12 |
mouse |
| Chia-Jui Yen, Julie G Izzo, Dung-Fang Lee, Sushovan Guha, Yongkun Wei, Tsung-Teh Wu, Chun-Te Chen, Hsu-Ping Kuo, Jung-Mao Hsu, Hui-Lung Sun, Chao-Kai Chou, Navtej S Buttar, Kenneth K Wang, Peng Huang, Jaffer Ajani, Mien-Chie Hun. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer research. vol 68. issue 8. 2008-06-10. PMID:18413730. |
to elucidate the molecular pathways of bile acid-induced tumorigenesis, the newly identified inflammation-associated signaling pathway involving i kappab kinases beta (ikk beta), tuberous sclerosis complex 1 (tsc1), and mammalian target of rapamycin (mtor) downstream effector s6 kinase (s6k1) was confirmed to be activated in immortalized barrett's cpc-a and cpc-c cells and esophageal cancer seg-1 and be3 cells. |
2008-06-10 |
2023-08-12 |
rat |
| Umut Ozcan, Lale Ozcan, Erkan Yilmaz, Katrin Düvel, Mustafa Sahin, Brendan D Manning, Gökhan S Hotamisligi. Loss of the tuberous sclerosis complex tumor suppressors triggers the unfolded protein response to regulate insulin signaling and apoptosis. Molecular cell. vol 29. issue 5. 2008-04-28. PMID:18342602. |
loss of the tuberous sclerosis complex genes (tsc1 or tsc2) leads to constitutive activation of mtor and downstream signaling elements, resulting in the development of tumors, neurological disorders, and at the cellular level, severe insulin/igf-1 resistance. |
2008-04-28 |
2023-08-12 |
mouse |
| Ai-Luen Wu, Jeong-Ho Kim, Chongben Zhang, Terry G Unterman, Jie Che. Forkhead box protein O1 negatively regulates skeletal myocyte differentiation through degradation of mammalian target of rapamycin pathway components. Endocrinology. vol 149. issue 3. 2008-04-22. PMID:18079193. |
inducible activation of a foxo1 active mutant in the c2c12 mouse myoblasts blocks myogenic differentiation at an early stage and meanwhile leads to proteasome-dependent degradation of a specific subset of components in the mtor signaling network, including mtor, raptor, tuberous sclerosis complex 2, and s6 protein kinase 1. |
2008-04-22 |
2023-08-12 |
mouse |